Jeannette Dabit, APRN
Family · Bowling Green, KYNPI 1477055853
Payments from drug & device makers
Across 645 payments — averaging $43.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Janssen Scientific Affairs, LLC$6K
- Amgen$4K
- Eli Lilly$2K
- UCB, Inc.$2K
- AbbVie$2K
- plus $6K from 25 others
What the payments were for
- Consulting fees$10,50138%
- Travel & lodging$2,4069%
- Food & beverage$14,56853%
- Education$2591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $6,817 |
| Janssen Scientific Affairs, LLC | 9 | $5,629 |
| Amgen(2 entities) | 152 | $4,267 |
| Eli Lilly | 1 | $2,100 |
| UCB, Inc. | 81 | $1,845 |
| AbbVie | 67 | $1,570 |
| Johnson & Johnson | 41 | $1,027 |
| Mallinckrodt Hospital Products Inc. | 39 | $855 |
| GSK | 38 | $712 |
| Radius Health, Inc. | 22 | $525 |
| Lilly USA, LLC | 22 | $441 |
| E.r. Squibb & Sons, L.L.C. | 22 | $368 |
| AstraZeneca(2 entities) | 17 | $336 |
| Pfizer | 17 | $289 |
| ANI Pharmaceuticals, Inc. | 6 | $138 |
| Organon | 7 | $111 |
| Boehringer Ingelheim | 5 | $98 |
| Aurinia Pharma U.S., Inc. | 5 | $97 |
| Sanofi | 4 | $96 |
| Sobi, Inc | 4 | $74 |
| Fresenius Kabi USA, LLC | 4 | $59 |
| Tonix Medicines, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $40 |
| Pacira Therapeutics, Inc. | 2 | $38 |
| Sandoz | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| Octapharma USA, Inc. | 1 | $21 |
| Bristol Myers Squibb | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,734 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 130 | $1,035,955 |
| RinvoqUpadacitinib | 77 | $519,259 |
| OtezlaApremilast | 80 | $399,532 |
| Humira(Cf) PenAdalimumab | 43 | $302,377 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 30 | $292,279 |
| Cosentyx Unoready PenSecukinumab | 22 | $274,569 |
| TremfyaGuselkumab | 17 | $228,567 |
| Orencia ClickjectAbatacept | 15 | $95,041 |
| Humira(Cf)Adalimumab | 13 | $91,173 |
| TymlosAbaloparatide | 24 | $89,102 |
| OzempicSemaglutide | 44 | $44,778 |
| ProliaDenosumab | 15 | $25,778 |
| MethotrexateMethotrexate Sodium | 506 | $13,846 |
| Hydroxychloroquine Sulfate | 464 | $13,676 |
| Leflunomide | 235 | $13,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,570 | $610,43290 claims |
| AmgenOtezla, Prolia | $4,267 | $425,30995 claims |
| Johnson & JohnsonTremfya | $1,027 | $228,56717 claims |
| Radius Health, Inc.Tymlos | $525 | $89,10224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Bowling Green
- Carrie Parrish NyekanBowling Green$55K
- Cory GearldsBowling Green$51K
- Shellie HardcastleBowling Green$15K
- Ashley ToweBowling Green$14K
- Ayme RowlandBowling Green$14K
- Jenna PoteetBowling Green$14K
- Jacqueline ErbseBowling Green$14K
- Krista NealBowling Green$12K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.